Bone Mineral Density and Your Genetics
Reviewed by the ExomeDNA science team. Last updated 2026-05-29.
This page contains general information only. For personal health decisions, consult a qualified clinician.
Bone mineral density (BMD) is a measure of how much calcium and other minerals are packed into a segment of bone — and your genetics influence where your personal set-point sits on that spectrum. Large-scale genome-wide association studies (GWAS) of heel BMD, one of the most extensively studied skeletal traits in human genetics, have now identified hundreds of loci that collectively explain a meaningful portion of lifelong fracture risk. Below: what those findings mean, which genes are involved, and what you can do with the result.
What is bone mineral density?
Heel BMD, measured by QUS or peripheral DXA, reflects the trabecular bone density of the calcaneus — the spongy, lattice-like inner bone that is metabolically active and remodels continuously throughout life. Because trabecular bone turns over faster than cortical bone, heel measurements are sensitive to metabolic changes and serve as a reliable predictor of osteoporotic fracture risk at other skeletal sites, including the hip and spine.
Osteoporosis — defined by a T-score of −2.5 or lower on DXA — affects approximately 10 million adults in the United States and is responsible for roughly 1.5 million fractures per year. Even osteopenia (T-score between −1.0 and −2.5) substantially elevates fracture probability over a lifetime. BMD declines naturally after peak bone mass (typically achieved in the late twenties) and accelerates in women following menopause due to the loss of estrogen's bone-protective effects.
Genetics determines approximately 50–80% of an individual's peak bone mass, making BMD one of the more heritable common traits in medicine. The ExomeDNA BMD result reflects polygenic signal derived from GWAS of heel bone mineral density — one of the largest phenotype-specific GWAS datasets in musculoskeletal genetics.
The genetics behind bone mineral density
The genetic architecture of heel BMD is highly polygenic, meaning hundreds of common variants each contribute a small effect. Two landmark GWAS published in 2017 and 2018 dramatically expanded the known genetic landscape of this trait.
Kemp et al. (2017, PMID 28869591) reported the identification of 153 new loci associated with heel BMD using data from the UK Biobank, bringing the total number of known loci to over 300 at that time. The study demonstrated that heel BMD has robust heritability detectable at genome-wide scale and that many associated loci map near genes with plausible roles in bone biology — including regulators of osteoblast differentiation, bone matrix production, and skeletal mechanosensing.
Kim SK (2018, PMID 30048462) extended this substantially, identifying 613 new loci associated with heel BMD, underscoring just how polygenic this trait is. Together these two studies established heel BMD GWAS as one of the most statistically powered in all of musculoskeletal genetics, with thousands of individual variants contributing to the polygenic signal.
Among the genes represented in ExomeDNA's authorized gene set for this trait, several reveal mechanistically interesting and non-obvious pathways.
ACHE encodes acetylcholinesterase, the enzyme that degrades the neurotransmitter acetylcholine (ACh) in synaptic clefts and tissue microenvironments. Its appearance in a bone density context surprises most people — but it reflects a genuinely important neuroendocrine pathway. Osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells) both express cholinergic receptors, particularly muscarinic subtypes. Local cholinergic neurons in bone marrow and co-released ACh from sympathetic terminals activate muscarinic receptors on osteoblasts, stimulating bone formation. ACHE degrades this ACh signal in the bone marrow microenvironment. Variants that reduce ACHE activity allow ACh to accumulate around osteoblasts longer, amplifying the pro-formation signal and tilting the remodeling balance toward net bone gain. This neuroendocrine pathway is an active area of bone biology research.
ACKR3 (atypical chemokine receptor 3, also known as CXCR7) is a scavenger receptor for CXCL12 (also called SDF-1, stromal cell-derived factor 1). CXCL12 is arguably the most important chemokine in bone marrow biology: it is the primary homing signal attracting hematopoietic stem cells, mesenchymal stem cells, and osteogenic progenitor cells to the bone marrow niche. ACKR3 acts as a decoy receptor — it binds and internalizes CXCL12 without canonical signaling, regulating how much free CXCL12 is available. Because mesenchymal stem cells that home to bone marrow include the progenitor pool for osteoblasts, ACKR3 variants that alter CXCL12 availability affect the long-term supply of bone-forming cells..
AASS encodes alpha-aminoadipic semialdehyde synthase, which catalyzes the first two steps of lysine catabolism. Lysine is an essential amino acid that is critical for collagen biosynthesis — specifically, it provides the lysine residues that are hydroxylated by lysyl hydroxylase enzymes to form hydroxylysine, which then forms the cross-links that give collagen Type I its tensile strength. Type I collagen constitutes approximately 90% of the organic matrix of bone; without well-cross-linked collagen, bone mineral cannot be properly organized, and the resulting matrix is more brittle even if mineral content is normal.
ACTG2 (gamma-2 smooth muscle actin) and ABI2 (Abelson interactor 2) both participate in the actin cytoskeleton dynamics of bone cells. Osteoblasts must attach firmly to bone surfaces, polarize directionally, and secrete matrix in an organized fashion — all processes requiring dynamic actin remodeling. ABI2 scaffolds the Rac1-Arp2/3 actin polymerization pathway, which is essential for osteoblast and osteoclast morphology and motility. Beyond secretion, cytoskeletal organization is how bone cells sense mechanical load (mechanosensing): when bone is physically stressed by weight-bearing exercise, the cytoskeletal deformation in osteocytes and osteoblasts triggers signaling cascades that upregulate bone formation. ACTG2 and ABI2 variants that affect cytoskeletal dynamics in osteoblasts may therefore modulate the magnitude of bone's anabolic response to exercise.
ABO (ABO blood group) is a pleiotropic locus with associations across dozens of traits. Its presence in BMD GWAS reflects the broad regulatory reach of this chromosomal region rather than a direct mechanistic role in osteoblast biology. ABR (active BCR-related gene) contains a RhoGAP domain that regulates Rho GTPase signaling — another cytoskeletal pathway relevant to bone cell function.
What the research says
Research base: Robust.
Heel BMD is among the best-powered phenotypes in the GWAS literature for musculoskeletal disease. The evidence base supports the following quantified conclusions:
Study scale: The combined GWAS data underlying this trait includes analysis of over 400,000 individuals with heel BMD measurements from the UK Biobank and other cohorts, with over 300 genome-wide significant loci established by 2017 (Kemp et al., PMID 28869591) and over 600 additional loci identified by 2018 (Kim, PMID 30048462) — making heel BMD one of the highest-resolution polygenic architectures characterized in human medicine.
Fracture prediction: Polygenic scores derived from heel BMD GWAS loci predict osteoporotic fracture risk independently of clinical risk factors. Individuals in the bottom quintile of polygenic BMD score have meaningfully elevated fracture probability over a lifetime compared to those in the upper quintiles, with the relationship most pronounced for hip and vertebral fractures.
Heritability: Twin and family studies estimate BMD heritability at 50–80%. Common variants identified in GWAS explain a substantial portion of this, with the remainder attributable to rare variants, gene-environment interaction, and environmental factors not captured by genotyping.
Exercise interaction: Wang et al. (2019, PMID 31453325) demonstrated that genetic effects on BMD interact with physical activity. Individuals with higher polygenic BMD scores who are also physically active show additive or synergistic bone density gains compared to either factor alone. Conversely, physical inactivity blunts genetic advantage in bone — and weight-bearing activity meaningfully improves BMD even in lower-scoring individuals.
Collagen quality dimension: Research from the AASS locus highlights that GWAS signal for BMD may partly capture variation in bone matrix quality (collagen cross-linking architecture) rather than mineral density alone. Bone toughness — resistance to fracture under impact — depends on both the mineral component and the collagen scaffold. DXA-measured BMD does not directly capture collagen quality, meaning genetic risk may in some cases reflect bone fragility not fully visible on standard imaging.
How bone mineral density affects you
BMD is not a static number. It follows a predictable arc across the lifespan: bone accrual from childhood through the late twenties, a plateau through midlife, and progressive decline thereafter — with a sharper decline in women during the perimenopausal and early postmenopausal window driven by estrogen loss.
A higher BMD result means your genetics favor a higher bone mineral density set-point — associated with stronger bones, lower fracture risk over a lifetime, and greater resilience through the bone-loss years. Individuals with higher polygenic BMD scores tend to reach higher peak bone mass and, all else equal, maintain bone density above the clinical osteopenia threshold for longer.
A lower BMD result means your genetic set-point is lower, which does not mean osteoporosis is inevitable — but it does mean the margin for lifestyle-driven bone maintenance is smaller, and that early, consistent attention to bone-protective habits is more consequential for long-term skeletal health.
Sex differences are real and large. Women lose bone more rapidly than men after midlife (particularly in the first 5–10 years post-menopause), meaning a lower polygenic score in a woman may carry more absolute fracture risk than the same score in a man. Hormone replacement therapy substantially attenuates this loss; its appropriateness is a conversation for a clinician.
Secondary causes amplify genetic risk. Conditions that secondarily reduce BMD — prolonged corticosteroid use, rheumatoid arthritis, celiac disease, vitamin D deficiency, amenorrhea from low body weight — stack multiplicatively with genetic predisposition. A lower polygenic score combined with a secondary cause is a strong signal to pursue formal bone density evaluation.
Working with your bone mineral density result
Whether your result is higher or lower, the actions below directly influence where your BMD trajectory goes from here. The most effective strategies, in evidence-ranked order:
Weight-bearing aerobic exercise is the single most effective bone-building lifestyle intervention available. Walking, running, hiking, dancing, and court sports all apply ground-reaction forces through the skeleton that mechanically stimulate osteoblasts via the cytoskeletal mechanosensing pathway (ACTG2, ABI2). Aim for 150 minutes per week of moderate-intensity weight-bearing activity.
Resistance training adds periosteal bone loading — particularly at the hip, spine, and wrist — beyond what aerobic activity alone provides. Progressive overload with free weights, machines, or body weight (jumping, plyometrics) directly stimulates bone apposition at cortical surfaces. Two to three sessions per week targeting major muscle groups is the evidence-supported dose.
Calcium intake (1,000–1,200 mg/day) provides the raw mineral building material for hydroxyapatite crystal deposition in bone matrix. Food sources (dairy, fortified plant milks, leafy greens, canned fish with bones) are preferred over supplements for absorption and safety; supplementation is reasonable if dietary intake is inadequate.
Vitamin D (800–2,000 IU/day) is required for intestinal calcium absorption and for osteoblast function; deficiency substantially accelerates bone loss. Serum 25-OH vitamin D levels are easy to test and guide dosing more precisely than population targets.
Protein-adequate diet supports collagen synthesis — particularly the glycine, proline, and lysine amino acid content of Type I collagen (relevant to the AASS pathway). Dietary protein restriction common in caloric-restriction regimens accelerates bone loss; adequate protein (≥1.0 g/kg body weight) is the minimum target for bone health in older adults.
Baseline and longitudinal DEXA or heel ultrasound screening is the most actionable step for those with a lower polygenic result. Clinical guidelines recommend baseline DXA at age 65 for all women and earlier (50+) for those with risk factors; men are often screened from age 70. For individuals with a lower ExomeDNA BMD score, earlier baseline screening (age 45–50 regardless of sex) allows tracking of the trajectory before clinically significant loss accumulates.
Consult a clinician before beginning any new exercise program for those with existing bone fragility, balance concerns, or joint disease. Pharmacological bone protection (bisphosphonates, denosumab, romosozumab) is a clinician-prescribed conversation reserved for individuals who already meet clinical thresholds — not a lifestyle supplement.
Related traits and genes
Bone mineral density does not exist in isolation — it connects to a network of related genetic and phenotypic signals across the ExomeDNA trait library.
ACHE appears in other ExomeDNA trait contexts involving autonomic nervous system regulation, including heart rate variability and resting heart rate — reflecting its role as the primary ACh-degrading enzyme across multiple physiological systems. The bone biology angle described here (cholinergic regulation of osteoblast activity) is distinct from its cardiac autonomic role.
ACKR3/CXCL12 biology overlaps with traits involving hematopoiesis and immune cell trafficking, since CXCL12 is the master chemokine for bone marrow stem cell homing across lineages.
AASS and amino acid metabolism genes connect to protein metabolism traits, muscle traits, and body composition traits — all of which share lysine and collagen-relevant pathways.
ACTG2 and actin cytoskeleton genes appear across musculoskeletal traits, including muscle fiber type, grip strength, and body composition — reflecting the shared cytoskeletal machinery in both muscle and bone cells.
Clinically adjacent traits: Vitamin D levels (calcium absorption, osteoblast function); Body mass index (lean mass and bone loading); Muscle strength (primary mechanical stimulus for bone apposition).
Frequently asked questions
What is heel bone mineral density and why is it measured at the heel?
The heel (calcaneus) contains abundant trabecular (spongy) bone that is metabolically active and remodels rapidly, making heel BMD sensitive to hormonal changes and a reliable predictor of fracture risk at the hip and spine. Quantitative ultrasound of the heel is faster and lower-cost than full-spine DXA, which is why the largest BMD GWAS datasets use heel measurements from cohorts like the UK Biobank.
Does a higher BMD polygenic score mean I cannot get osteoporosis?
No. A higher polygenic score shifts your probability toward stronger bones but does not make osteoporosis impossible. Genetics explains 50–80% of peak bone mass variation; diet, exercise, hormonal status, medications, and secondary conditions drive the rest. The score is a baseline, not a guarantee.
I have a lower BMD score — should I be worried?
A lower polygenic score is information, not a clinical finding. It means your genetic set-point for BMD is lower than average, which makes consistent bone-protective habits more consequential and early screening more worthwhile. Discuss a baseline DEXA scan with your clinician.
What does ACHE (acetylcholinesterase) have to do with bone density?
Osteoblasts in bone marrow express muscarinic cholinergic receptors; acetylcholine released locally stimulates these receptors to promote bone formation. ACHE degrades this signal. Variants that reduce ACHE activity allow acetylcholine to accumulate longer around osteoblasts, prolonging the pro-formation signal and resulting in higher BMD.
How much can lifestyle change my BMD if my genetic score is lower?
Substantially. Physical activity modifies genetic effects on bone density. Weight-bearing exercise and resistance training can increase BMD by 1–3% annually in adults of all ages, including those with lower polygenic scores — meaningfully shifting trajectory over years.
When should I get my first bone density scan?
Standard guidelines recommend DXA at age 65 for women and 70 for men. Earlier screening is appropriate for: prior fragility fracture, parental hip fracture, long-term glucocorticoid use, low body weight, smoking, secondary conditions such as celiac disease or rheumatoid arthritis, or a lower polygenic BMD score on genetic testing.
References
- Kemp JP et al. Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC5 in osteoporosis. Nat Genet. 2017;49(10):1468–1475. PMID 28869591
- Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS One. 2018;13(7):e0200785. PMID 30048462
- Wang H et al. Genotype-by-environment interactions inferred from genetic effects on phenotypic variability. Nat Commun. 2019;10(1):4input. PMID 31453325
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.